Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-KIT, a new molecular entity, for...

Related Keywords

United States ,Robb Knie ,Glenn Cruse ,Nasdaq ,Prnewswire Hoth Therapeutics Inc ,Nc State University ,Professor At North Carolina State University ,Lr Advisors ,Exchange Commission ,Hoth Therapeutics Inc ,After Exposure ,Positive Results ,Preclinical Results ,Orphan Drug Designation ,Assistant Professor ,North Carolina State University ,Drug Designation ,Hoth Therapeutics ,Looking Statement ,Private Securities Litigation Reform Act ,Annual Report ,Nc ,